Adherence to clotting factors among persons with hemophilia A or B

Edward P Armstrong, Daniel C Malone, Sangeeta Krishnan, Maj J acob Wessler

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE: Evaluate adherence to clotting factor treatment and associated outcomes for patients with hemophilia using an integrated delivery database.

METHODS: This was a retrospective, observational study tracking patients between 2006 and 2011. Patients with diagnosis codes for hemophilia were identified. Bleeding and complication rates were annualized over the study period. Medication adherence was assessed using prescription claims for clotting factors by examining sequential time periods of 180 days for each patient's continuous enrollment. Adherence within the time period was calculated using the 'days supply' field divided by 180 days. Under the assumption that severe patients should be treated prophylactically, patients were considered adherent within the time period if the ratio of 'days supply' to observed days was 60% or greater.

RESULTS: A total of 207 patients (74.9 and 25.1% hemophilia A and B, respectively) met the inclusion/exclusion criteria. There were 101 (48.8%) mild, 32 (15.5%) moderate, and 74 (35.7%) severe patients with hemophilia. The percentage of time periods where adherence to clotting factors was 60% or greater was 14% (SD = 28%) for mild disease, 21% (SD = 32%) for moderate disease, and 51% (SD = 36%) for severe disease. Among patients with severe disease, 27 (36.5%) were adherent ≤ 30% of time periods, 22 (29.7%) adherent 31-70% of the time periods, and 25 (33.8%) were adherent ≥ 71% of time periods. Joint bleeding episodes and hospitalizations were uncommon events among the three groups.

CONCLUSIONS: Among patients with severe disease, the majority (66.2%) were adherent

Original languageEnglish (US)
Pages (from-to)148-153
Number of pages6
JournalHematology
Volume20
Issue number3
DOIs
StatePublished - Apr 1 2015

Fingerprint

Hemophilia B
Blood Coagulation Factors
Hemophilia A
Patient Identification Systems
Hemorrhage
Medication Adherence
Observational Studies
Prescriptions
Hospitalization
Retrospective Studies
Joints
Databases

Keywords

  • Bleeding
  • Compliance
  • Hemophilia
  • Medication adherence
  • Pharmacy
  • Regimens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adherence to clotting factors among persons with hemophilia A or B. / Armstrong, Edward P; Malone, Daniel C; Krishnan, Sangeeta; Wessler, Maj J acob.

In: Hematology, Vol. 20, No. 3, 01.04.2015, p. 148-153.

Research output: Contribution to journalArticle

Armstrong, Edward P ; Malone, Daniel C ; Krishnan, Sangeeta ; Wessler, Maj J acob. / Adherence to clotting factors among persons with hemophilia A or B. In: Hematology. 2015 ; Vol. 20, No. 3. pp. 148-153.
@article{15b0a1a3d4044e9fa2383cc5a06d6fa8,
title = "Adherence to clotting factors among persons with hemophilia A or B",
abstract = "OBJECTIVE: Evaluate adherence to clotting factor treatment and associated outcomes for patients with hemophilia using an integrated delivery database.METHODS: This was a retrospective, observational study tracking patients between 2006 and 2011. Patients with diagnosis codes for hemophilia were identified. Bleeding and complication rates were annualized over the study period. Medication adherence was assessed using prescription claims for clotting factors by examining sequential time periods of 180 days for each patient's continuous enrollment. Adherence within the time period was calculated using the 'days supply' field divided by 180 days. Under the assumption that severe patients should be treated prophylactically, patients were considered adherent within the time period if the ratio of 'days supply' to observed days was 60{\%} or greater.RESULTS: A total of 207 patients (74.9 and 25.1{\%} hemophilia A and B, respectively) met the inclusion/exclusion criteria. There were 101 (48.8{\%}) mild, 32 (15.5{\%}) moderate, and 74 (35.7{\%}) severe patients with hemophilia. The percentage of time periods where adherence to clotting factors was 60{\%} or greater was 14{\%} (SD = 28{\%}) for mild disease, 21{\%} (SD = 32{\%}) for moderate disease, and 51{\%} (SD = 36{\%}) for severe disease. Among patients with severe disease, 27 (36.5{\%}) were adherent ≤ 30{\%} of time periods, 22 (29.7{\%}) adherent 31-70{\%} of the time periods, and 25 (33.8{\%}) were adherent ≥ 71{\%} of time periods. Joint bleeding episodes and hospitalizations were uncommon events among the three groups.CONCLUSIONS: Among patients with severe disease, the majority (66.2{\%}) were adherent",
keywords = "Bleeding, Compliance, Hemophilia, Medication adherence, Pharmacy, Regimens",
author = "Armstrong, {Edward P} and Malone, {Daniel C} and Sangeeta Krishnan and Wessler, {Maj J acob}",
year = "2015",
month = "4",
day = "1",
doi = "10.1179/1607845414Y.0000000176",
language = "English (US)",
volume = "20",
pages = "148--153",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Adherence to clotting factors among persons with hemophilia A or B

AU - Armstrong, Edward P

AU - Malone, Daniel C

AU - Krishnan, Sangeeta

AU - Wessler, Maj J acob

PY - 2015/4/1

Y1 - 2015/4/1

N2 - OBJECTIVE: Evaluate adherence to clotting factor treatment and associated outcomes for patients with hemophilia using an integrated delivery database.METHODS: This was a retrospective, observational study tracking patients between 2006 and 2011. Patients with diagnosis codes for hemophilia were identified. Bleeding and complication rates were annualized over the study period. Medication adherence was assessed using prescription claims for clotting factors by examining sequential time periods of 180 days for each patient's continuous enrollment. Adherence within the time period was calculated using the 'days supply' field divided by 180 days. Under the assumption that severe patients should be treated prophylactically, patients were considered adherent within the time period if the ratio of 'days supply' to observed days was 60% or greater.RESULTS: A total of 207 patients (74.9 and 25.1% hemophilia A and B, respectively) met the inclusion/exclusion criteria. There were 101 (48.8%) mild, 32 (15.5%) moderate, and 74 (35.7%) severe patients with hemophilia. The percentage of time periods where adherence to clotting factors was 60% or greater was 14% (SD = 28%) for mild disease, 21% (SD = 32%) for moderate disease, and 51% (SD = 36%) for severe disease. Among patients with severe disease, 27 (36.5%) were adherent ≤ 30% of time periods, 22 (29.7%) adherent 31-70% of the time periods, and 25 (33.8%) were adherent ≥ 71% of time periods. Joint bleeding episodes and hospitalizations were uncommon events among the three groups.CONCLUSIONS: Among patients with severe disease, the majority (66.2%) were adherent

AB - OBJECTIVE: Evaluate adherence to clotting factor treatment and associated outcomes for patients with hemophilia using an integrated delivery database.METHODS: This was a retrospective, observational study tracking patients between 2006 and 2011. Patients with diagnosis codes for hemophilia were identified. Bleeding and complication rates were annualized over the study period. Medication adherence was assessed using prescription claims for clotting factors by examining sequential time periods of 180 days for each patient's continuous enrollment. Adherence within the time period was calculated using the 'days supply' field divided by 180 days. Under the assumption that severe patients should be treated prophylactically, patients were considered adherent within the time period if the ratio of 'days supply' to observed days was 60% or greater.RESULTS: A total of 207 patients (74.9 and 25.1% hemophilia A and B, respectively) met the inclusion/exclusion criteria. There were 101 (48.8%) mild, 32 (15.5%) moderate, and 74 (35.7%) severe patients with hemophilia. The percentage of time periods where adherence to clotting factors was 60% or greater was 14% (SD = 28%) for mild disease, 21% (SD = 32%) for moderate disease, and 51% (SD = 36%) for severe disease. Among patients with severe disease, 27 (36.5%) were adherent ≤ 30% of time periods, 22 (29.7%) adherent 31-70% of the time periods, and 25 (33.8%) were adherent ≥ 71% of time periods. Joint bleeding episodes and hospitalizations were uncommon events among the three groups.CONCLUSIONS: Among patients with severe disease, the majority (66.2%) were adherent

KW - Bleeding

KW - Compliance

KW - Hemophilia

KW - Medication adherence

KW - Pharmacy

KW - Regimens

UR - http://www.scopus.com/inward/record.url?scp=84952327083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952327083&partnerID=8YFLogxK

U2 - 10.1179/1607845414Y.0000000176

DO - 10.1179/1607845414Y.0000000176

M3 - Article

C2 - 25001343

AN - SCOPUS:84952327083

VL - 20

SP - 148

EP - 153

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - 3

ER -